MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 10:58 pm EST
Share
MYUNGMOON Pharm co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 1,971.6 million compared to KRW 2,209.14 million a year ago. Net loss was KRW 938.9 million compared to net income of KRW 93.93 million a year ago. Basic loss per share from continuing operations was KRW 28 compared to basic earnings per share from continuing operations of KRW 3 a year ago. Basic loss per share was KRW 28 compared to basic earnings per share of KRW 3 a year ago.
For the nine months, sales was KRW 6,197.42 million compared to KRW 6,372.39 million a year ago. Net loss was KRW 493.16 million compared to net income of KRW 3,235.24 million a year ago. Basic loss per share from continuing operations was KRW 15 compared to basic earnings per share from continuing operations of KRW 96 a year ago. Basic loss per share was KRW 15 compared to basic earnings per share of KRW 96 a year ago.
MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.